Pharmaceuticals, Biotechnology and Life Sciences
Amryt has reported $44.6M unaudited Q1 revenues representing 30% for the first quarter ended March 31, 2020. The net loss for the period was $17.0M, compared to 2.8 in the same period last year.
Amryt said that Scheme has been sanctioned by the High Court of Justice in England and Wales and the Scheme Court Order is expected to be filed with the Registrar of Companies on 24 September 2019, at which point the Scheme will become effective.
Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.
Amryt ensure US Food and Drug Administration’s grant a Rare Pediatric Disease designation for its lead development asset AP101, for…
Joe Wiley, CEO of Amryt, said Amryt has an ambitious plans for the remainder of 2018 as it looks forward to…
Amryt has expanded its market coverage for Lojuxta with an exclusive distribution agreement for Lebanon, Jordan and Syria, as it…
Amryt has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (Romastru), a…
Amryt has paved its way for marketing for Lojuxta by signing a deal with with GryNumber Health. The exclusive distribution…
Amryt, a biopharmaceutical company focused on rare and orphan diseases, has signed an agreement for distributing its Lojuxta through RCC…
Amryt Pharma, a biopharmaceutical company focused on rare and orphan diseases, has appointed Kieran Rooney, as Vice President of Strategic Alliances and Licensing.